Navigation Links
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Date:9/25/2008

4.40 kg and 2.45+/-4.37 kg occurred with liraglutide 1.2 mg and 1.8 mg, respectively, versus a weight gain of 1.12+/-4.24 kg with glimepiride.

There were no major hypoglycemic episodes reported during the study. The rate of minor hypoglycemia was statistically significantly lower in both liraglutide dose groups compared with the glimepiride-treated group. The most common gastrointestinal-related adverse events with liraglutide were nausea, diarrhea and vomiting, and most were transient. Other adverse events reported included flu-like symptoms.

About Liraglutide

Liraglutide is a once-daily human analog of the naturally occurring hormone Glucagon-Like Peptide-1 (GLP-1). Liraglutide works by stimulating the release of insulin only when blood sugar levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States as well as a marketing authorization application to the European Medicines Agency in Europe for the approval of liraglutide for the treatment of patients with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) 3a program involved about 4000 patients with type 2 diabetes in 40 countries.

The data published early online and in an upcoming edition of The Lancet is from the LEAD(TM) 3 study, one of five randomized, controlled, double-blinded studies that make up the phase 3a program for liraglutide.

Data from the LEAD(TM) 3 study have previously been reported on by Novo Nordisk in a Stock Exchange Announcement on December 11, 2007, and in a press release on June 9, 2008, in connection with the American Diabetes Association meeting in San Francisco.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabe
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... 2014 Somewhere between dropping five pounds and ... But Audicus , a next-generation hearing aids company, ... year. Hearing loss is the third most ... it is often unaddressed. Forty-eight million Americans have hearing ... aid, mainly due to price. Hearing aids traditionally cost ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... DIEGO, Aug. 8, 2011 CareFusion Corp. (NYSE: ... results for the quarter and fiscal year ended June 30, ... Prevention businesses, gross margin expansion and the benefit of strong ... earnings for the quarter and for the year," said Kieran ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... June 30, 2011. Quarterly Financial Highlights ... revenue for NUEDEXTA® of $2.2 million Cash, cash equivalents, and ... "I am thrilled with the progress we are making ...
Cached Medicine Technology:CareFusion Reports Fourth Quarter and Fiscal 2011 Results 2CareFusion Reports Fourth Quarter and Fiscal 2011 Results 3CareFusion Reports Fourth Quarter and Fiscal 2011 Results 4CareFusion Reports Fourth Quarter and Fiscal 2011 Results 5CareFusion Reports Fourth Quarter and Fiscal 2011 Results 6CareFusion Reports Fourth Quarter and Fiscal 2011 Results 7CareFusion Reports Fourth Quarter and Fiscal 2011 Results 8CareFusion Reports Fourth Quarter and Fiscal 2011 Results 9CareFusion Reports Fourth Quarter and Fiscal 2011 Results 10CareFusion Reports Fourth Quarter and Fiscal 2011 Results 11CareFusion Reports Fourth Quarter and Fiscal 2011 Results 12CareFusion Reports Fourth Quarter and Fiscal 2011 Results 13CareFusion Reports Fourth Quarter and Fiscal 2011 Results 14CareFusion Reports Fourth Quarter and Fiscal 2011 Results 15Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 2Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 3Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 4Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 5Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 6Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 7Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results 8
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... York, New York (PRWEB) December 21, 2014 ... ) and other product liability claims involving a ... incretin mimetics continue to move forward in a ... Court, Southern District of California, Bernstein Liebhard LLP ... the Court has established a data cut-off date ...
(Date:12/21/2014)... The number of Mirena lawsuits ( ... underway in New Jersey, Bernstein Liebhard LLP reports. , ... involving the birth control IUD have now been filed ... by women who allege spontaneous migration of the device, ... and other complications they were inadequately warned about by ...
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... Theme and plugin developers from ... for Final Cut Pro X entitled ProMotion. , “ProMotion ... with absolute ease.” Said Christiana Austin, CEO of Pixel ... to easily animate their media inside FCPX.” , Pixel ... to animate pictures, videos, logos, and more with absolute ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... release is available in Spanish . , What ... a disease? What affects the ideas and beliefs that patients ... Granada have developed a test for measuring and assessing ... enable the development of clinical psychological treatments much more efficient ...
... HealthDay Reporter , WEDNESDAY, Oct. 20 (HealthDay News) ... for new warnings on the labels of widely used hormonal ... risk of heart disease and diabetes in the men who ... it was reviewing the prostate cancer drugs known as gonadotropin-releasing ...
... Calif.) A study of the options for reducing ... treated for precancerous cervical lesions found that an annual ... Joy Melnikow, professor in the Department of Family ... strategies for the 500,000 American women diagnosed and treated ...
... Computed tomography colonography (CTC) otherwise known as virtual ... optimal colonoscopy is limited, according to a study in ... ( www.ajronline.org ). The study was performed ... and Tuba City Regional Health Care Center in Tuba ...
... Oct. 20 -- Scientists and engineers from around the world ... N.Y. next week to discuss some of the latest breakthroughs ... the development of new materials, and medicine. Journalists are ... the 94th annual meeting of the Optical Society (OSA), which ...
... Oct. 20 (HealthDay News) -- Fatalism, a belief that life,s ... have some of the lowest cancer screening rates in the ... more likely than white women to believe that cancer is ... with cancer, the researchers found. Karla Espinosa de los ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 3Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Fatalistic Attitudes May Keep Hispanic Women From Cancer Tests 2
... HEp-2000 ANA uses a patented HEp-2 ... to increase the sensitivity to SS-A/Ro autoantibodies, ... Several independent studies have been published worldwide ... increased sensitivity to SS-A/Ro autoantibodies when used ...
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... The ANA and ENA assays can ... negative for antinuclear antibodies, which are ... such as Systemic lupus erythematosus (Lupus), ... progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, ...
... Indirect Fluorescence Assay (IFA) for IgG ... for the qualitative and semi-quantitative detection ... in human serum. Detection of ANA ... an aid in the diagnosis of ...
Medicine Products: